Aquestive Therapeutics, Inc. (AQST) Stock Analysis and Metrics

Aquestive Therapeutics

NASDAQ: AQST

$3.68 ▼ -0.09 (-2.25%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap453.66 Mn

P/E-6.58

P/S68.08

Div. Yield0.00

Total Debt (Qtr)58.66 Mn

Add ratio to table…

About

Aquestive Therapeutics, Inc. is a pharmaceutical company developing medicines through innovative drug delivery technologies. The company focuses on creating alternative administration methods for complex molecules to replace standard of care therapies. Its primary activities involve its proprietary PharmFilm oral film technology and AdrenaVerse epinephrine prodrug platform alongside manufacturing and supplying licensed commercial products to pharmaceutical partners.

Aquestive Therapeutics, Inc. generates revenue primarily by manufacturing and supplying its licensed commercial products to pharmaceutical partners. Key products include Suboxone for opioid dependence treatment Emylif for ALS Ondif for nausea and vomiting and Sympazan for seizures associated with Lennox Gastaut syndrome. The company also earns revenue from milestone payments and royalties under licensing agreements with licensed product revenue totaling $44.5 million in 2025.

Aquestive Therapeutics, Inc. holds a leading position in oral film drug delivery as the worldwide supplier of the majority of prescription pharmaceutical oral films. In the epinephrine delivery market for allergic reactions it competes with products such as EpiPen marketed by Teva and Auvi Q marketed by Kaleo as well as the recently approved nasal spray neffy from ARS Pharmaceuticals. For epilepsy rescue therapies its Libervant product competes with diazepam rectal gel and nasal spray formulations though it has faced regulatory challenges related to orphan drug exclusivity with Valtoco. Competitive advantages stem from its proprietary drug delivery technologies that offer improved patient convenience reduced gastrointestinal side effects and potential for better therapeutic outcomes compared to traditional administration methods.

Aquestive Therapeutics, Inc. serves pharmaceutical companies through licensing and manufacturing agreements. Specific named customers include Indivior for Suboxone Zambon for Emylif in European markets and Otter Pharmaceuticals a subsidiary of Assertio Holdings for Sympazan. The company has previously maintained licensing agreements with MTPA and Haisco for Exservan in the United States and China. For its proprietary product candidates in development the intended customers are patients and healthcare providers in emergency allergy treatment and epilepsy management.

Investment Thesis

▲ Bull case

AQST's strategic positioning with Anaphylm represents a significant undervalued opportunity as the company has completed all prerequisite regulatory interactions including FDA Type A meeting, MHRA teleconference, and EMA pediatric investigational plan submission without requiring additional clinical studies, creating a clear path to resubmission in Q3 FY26 with potential for accelerated review given the limited nature of the required human factors and PK studies, which management explicitly noted could warrant less than the standard 6-month timeline based on recent precedents in the epinephrine space, thereby de-risking the near-term approval catalyst that the market may be overlooking amid broader biotech volatility.
The company's liquidity runway is substantially stronger than perceived, with the $150 million Oaktree debt facility providing immediate refinancing benefits including reduced interest rates and extended interest-only periods that save $45 million in principal payments over three years, while simultaneously unlocking access to $20 million in additional capital upon FDA approval of Anaphylm, and when combined with existing cash reserves and the RTW funding agreement extended through June 2027, positions AQST to launch with greater than $150 million in cash before considering ex-U.S. out-licensing potential, eliminating financing concerns as a barrier to commercial execution.
AQST's commercial strategy demonstrates deep market insight through lessons learned from competitor launches, with specific focus on reducing physician office friction via best-in-class hub and patient support services, evidenced by HCP awareness increasing from 33% to 66% through proactive medical affairs engagement at over 40 planned conferences and 20 publications this year, creating a foundation for rapid adoption that addresses the critical allergen prescribing bottleneck where trust and clarity with allergists—not just product innovation—determine market success, a nuance the market may underestimate in its valuation of launch readiness.
The AdrenaVerse platform's expansion potential via AQST-108 presents a hidden value driver, as early Phase I data showed directional impact on TSLP—a cytokine upstream of JAK1/JAK2 signaling—in subjects with alopecia areata, suggesting broad immunomodulatory potential without systemic absorption risks observed with oral JAK inhibitors, and management's commitment to prioritize this program post-Anaphylm resubmission indicates a near-term catalyst for pipeline diversification that could unlock multiple dermatological indications beyond the initial androgenic alopecia focus, representing optionality not reflected in current valuations.
International market access for Anaphylm is significantly derisked, with confirmed sufficiency of existing clinical data for filings in Canada, the U.K., and the U.K. and European Union requiring additional studies, enabling parallel regulatory pathways that could make the product available to nearly 1 billion people across these jurisdictions upon approval, with management targeting 2026 filings in both Canada and Europe and retaining favorable economics through partnership discussions, creating substantial ex-U.S. revenue potential that remains unpriced into the current U.S.-centric market assessment.

AQST's strategic positioning with Anaphylm represents a significant undervalued opportunity as the company has completed all prerequisite regulatory interactions including FDA Type A meeting, MHRA teleconference, and EMA pediatric investigational plan submission without requiring additional clinical studies, creating a clear path to resubmission in Q3 FY26 with potential for accelerated review given the limited nature of the required human factors and PK studies, which management explicitly noted could warrant less than the standard 6-month timeline based on recent precedents in the epinephrine space, thereby de-risking the near-term approval catalyst that the market may be overlooking amid broader biotech volatility.
The company's liquidity runway is substantially stronger than perceived, with the $150 million Oaktree debt facility providing immediate refinancing benefits including reduced interest rates and extended interest-only periods that save $45 million in principal payments over three years, while simultaneously unlocking access to $20 million in additional capital upon FDA approval of Anaphylm, and when combined with existing cash reserves and the RTW funding agreement extended through June 2027, positions AQST to launch with greater than $150 million in cash before considering ex-U.S. out-licensing potential, eliminating financing concerns as a barrier to commercial execution.
AQST's commercial strategy demonstrates deep market insight through lessons learned from competitor launches, with specific focus on reducing physician office friction via best-in-class hub and patient support services, evidenced by HCP awareness increasing from 33% to 66% through proactive medical affairs engagement at over 40 planned conferences and 20 publications this year, creating a foundation for rapid adoption that addresses the critical allergen prescribing bottleneck where trust and clarity with allergists—not just product innovation—determine market success, a nuance the market may underestimate in its valuation of launch readiness.
The AdrenaVerse platform's expansion potential via AQST-108 presents a hidden value driver, as early Phase I data showed directional impact on TSLP—a cytokine upstream of JAK1/JAK2 signaling—in subjects with alopecia areata, suggesting broad immunomodulatory potential without systemic absorption risks observed with oral JAK inhibitors, and management's commitment to prioritize this program post-Anaphylm resubmission indicates a near-term catalyst for pipeline diversification that could unlock multiple dermatological indications beyond the initial androgenic alopecia focus, representing optionality not reflected in current valuations.
International market access for Anaphylm is significantly derisked, with confirmed sufficiency of existing clinical data for filings in Canada, the U.K., and the U.K. and European Union requiring additional studies, enabling parallel regulatory pathways that could make the product available to nearly 1 billion people across these jurisdictions upon approval, with management targeting 2026 filings in both Canada and Europe and retaining favorable economics through partnership discussions, creating substantial ex-U.S. revenue potential that remains unpriced into the current U.S.-centric market assessment.

▼ Bear case

AQST's reliance on FDA feedback timing for its human factors protocol introduces material execution risk, as management explicitly acknowledged that the Q3 FY26 resubmission guidance and potential for accelerated review are contingent on the FDA providing timely and favorable responses within expectations—a variable outside the company's control—yet the discussion lacked concrete contingency plans for delays, suggesting potential overconfidence in regulatory alignment despite the historical unpredictability of FDA review cycles, which could push launch timelines into FY27 and erode the near-term cash runway benefits highlighted in the bullish case.
While the Oaktree financing improves debt terms, the structure creates future dilution and performance-linked risks, with Tranche B ($20 million) contingent solely on FDA approval of Anaphylm, Tranche C ($25 million) tied to unspecified sales thresholds, and Tranche D ($50 million) requiring mutual consent with Oaktree, meaning access to the full facility is not guaranteed and could be withheld if commercial execution falters, while the extended interest-only period merely defers principal repayment obligations that will eventually pressure cash flows if Anaphylm launch underperforms relative to the $150 million+ launch cash projection.
The commercial strategy's focus on reducing physician office friction, while informed by competitor launches like Neffy, remains unproven at scale, as management admitted to holding back specific playbook elements and acknowledged that awareness (now at 66% HCP recognition) does not equate to prescribing belief or real-world physician experience, with no disclosed metrics on actual prescription conversion rates or payer engagement depth, suggesting the launch may face significant adoption barriers despite medical affairs efforts, particularly given the entrenched incumbent devices and the critical need for allergist trust in a high-stakes emergency therapy category.
AQST-108's TSLP biomarker signal, while scientifically intriguing, remains highly speculative and early-stage, with management explicitly characterizing the Phase I data as directionally only and not statistically powered, coupled with the admission that future biomarker expansion will only occur after Anaphylm resubmission is prioritized, indicating a significant delay in pipeline validation that could extend beyond FY26, and the theoretical advantage of topical delivery avoiding systemic JAK inhibition risks remains unproven in human efficacy studies, leaving the program vulnerable to failure in atopic dermatitis or alopecia areata trials does not translate the preliminary mechanistic signal.
Ex-U.S. expansion plans, while promising on paper, face substantial unaddressed hurdles, as management's confidence in filing sufficiency for Canada, the U.K., and the EU relies on historical clinical data alignment without disclosing any recent feedback from MHRA or EMA on potential gaps, and the plan to avoid additional studies assumes regulatory stability that could shift abruptly—particularly in the EU post-Brexit and amid evolving EMA guidance—while partnership negotiations in Europe and South America remain in active stages with no disclosed timelines or economic terms, creating uncertainty around retained economics and actual market access speed that could delay or diminish the projected 1 billion person reach.

AQST's reliance on FDA feedback timing for its human factors protocol introduces material execution risk, as management explicitly acknowledged that the Q3 FY26 resubmission guidance and potential for accelerated review are contingent on the FDA providing timely and favorable responses within expectations—a variable outside the company's control—yet the discussion lacked concrete contingency plans for delays, suggesting potential overconfidence in regulatory alignment despite the historical unpredictability of FDA review cycles, which could push launch timelines into FY27 and erode the near-term cash runway benefits highlighted in the bullish case.
While the Oaktree financing improves debt terms, the structure creates future dilution and performance-linked risks, with Tranche B ($20 million) contingent solely on FDA approval of Anaphylm, Tranche C ($25 million) tied to unspecified sales thresholds, and Tranche D ($50 million) requiring mutual consent with Oaktree, meaning access to the full facility is not guaranteed and could be withheld if commercial execution falters, while the extended interest-only period merely defers principal repayment obligations that will eventually pressure cash flows if Anaphylm launch underperforms relative to the $150 million+ launch cash projection.
The commercial strategy's focus on reducing physician office friction, while informed by competitor launches like Neffy, remains unproven at scale, as management admitted to holding back specific playbook elements and acknowledged that awareness (now at 66% HCP recognition) does not equate to prescribing belief or real-world physician experience, with no disclosed metrics on actual prescription conversion rates or payer engagement depth, suggesting the launch may face significant adoption barriers despite medical affairs efforts, particularly given the entrenched incumbent devices and the critical need for allergist trust in a high-stakes emergency therapy category.
AQST-108's TSLP biomarker signal, while scientifically intriguing, remains highly speculative and early-stage, with management explicitly characterizing the Phase I data as directionally only and not statistically powered, coupled with the admission that future biomarker expansion will only occur after Anaphylm resubmission is prioritized, indicating a significant delay in pipeline validation that could extend beyond FY26, and the theoretical advantage of topical delivery avoiding systemic JAK inhibition risks remains unproven in human efficacy studies, leaving the program vulnerable to failure in atopic dermatitis or alopecia areata trials does not translate the preliminary mechanistic signal.
Ex-U.S. expansion plans, while promising on paper, face substantial unaddressed hurdles, as management's confidence in filing sufficiency for Canada, the U.K., and the EU relies on historical clinical data alignment without disclosing any recent feedback from MHRA or EMA on potential gaps, and the plan to avoid additional studies assumes regulatory stability that could shift abruptly—particularly in the EU post-Brexit and amid evolving EMA guidance—while partnership negotiations in Europe and South America remain in active stages with no disclosed timelines or economic terms, creating uncertainty around retained economics and actual market access speed that could delay or diminish the projected 1 billion person reach.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password